Abstract Because mutations in the murine analog of human LPIN1 cause lipodystrophy in mice, LPIN1 is a candidate gene for human lipodystrophy syndromes. To identify possible disease mutations and/or common singlenucleotide polymorphisms (SNPs), we developed primer pairs to amplify the 21 exons of LPIN1. We used these primer pairs to sequence LPIN1 in lipodystrophy patients who had no mutations in known lipodystrophy genes, and also in normal control subjects. We found no rare LPIN1 coding sequence variants that were exclusive to patients with lipodystrophy. However, we found four silent SNPs, namely, ϩ17CϾT in exon 3, 935CϾT in exon 5, and 1040GϾA and 1079GϾC in exon 6, and one nonsynonymous SNP, namely, 2211CϾT (P616S) in exon 15. The findings suggest that LPIN1 mutations are not commonly seen in patients with lipodystrophy who had no mutations in known disease genes. However, the identification of amplification primers and SNPs provides tools to further investigate LPIN1 for association with other phenotypes.
Introduction
Lipodystrophy refers to a heterogeneous group of disorders characterized by loss of body fat, insulin resistance, dyslipidemia, hypertension, diabetes, and atherosclerosis (Hegele 2001) . Two forms of lipodystrophy have been characterized at the molecular genetic level. The first is Dunnigan-type familial partial lipodystrophy (FPLD; MIM 151660), which is due to mutations in the LMNA gene (Cao and Hegele 2000; MIM 150330 ). The second is BerardinelliSeip complete lipodystrophy (BSCL; MIM 260700), which results from mutations in the BSCL2 gene (Magre et al. 2001 ; MIM 606158) in some families. However, there is another locus for BSCL called BSCL1 (Garg et al. 1999; MIM 606166) and, similarly there might be other loci for FPLD. Thus, it remains important to evaluate new candidate genes for lipodystrophy syndromes based on function, expression, genetic map position, and/or analogy with other human or animal phenotypes.
Mice carrying mutations in the fatty liver dystrophy ( fld) gene have features of human lipodystrophy (Reue et al. 2000) . Last year, the murine fld gene was isolated and two mutant alleles were characterized (Peterfy et al. 2001 ). The murine gene was designated Lpin1 and the novel nuclear protein gene product was designated lipin (Peterfy et al. 2001) . Database analysis identified several mouse and human sequences with similarities to Lpin1, including two Lpin1-related mouse genes called Lpin2 and Lpin3, and three human homologs called LPIN1 (MIM 605518), LPIN2 (MIM 605519), and LPIN3 (MIM 605520). LPIN1 is identical to the KIAA0188 gene (Nagase et al. 1996) , and maps to chromosome 2p21 (Peterfy et al. 2001) . Because of the findings in the mouse, the product of LPIN1 appears to be required for normal adipose tissue development, and thus represents a candidate gene for human lipodystrophy. To identify possible disease mutations and/or common singlenucleotide polymorphisms (SNPs), we sequenced LPIN1 in (1) lipodystrophic patients with no sequence abnormality in known lipodystrophy genes and (2) normal controls.
Subjects and methods

Study subjects
We studied 11 subjects with typical FPLD and 4 subjects with apparently typical BSCL. All subjects had normal se-quences of both the LMNA and BSCL2 genes. All affected subjects were of European descent. Subjects with acquired or drug-induced lipodystrophy were excluded. All subjects were isolated affected cases, and none came from a family that was sufficiently large to perform linkage analysis. In addition, samples from 100 clinically normal Caucasian subjects were screened to determine SNP allele frequencies. The study was approved by the Ethics Review Panel, University of Western Ontario.
Screening the LPIN1 gene for DNA variants
To amplify coding regions and intron-exon boundaries from genomic DNA, we developed a primer set using GenBank accession numbers XM_041136 and 17444450. Primer sequences are shown in Table 1 . Amplification conditions for all exons were as follows: 94°C for 5 min, followed by 30 cycles of 30 s each at 94°C, 60°C, and 72°C, and ending with a single 10-min extension step at 72°C.
Genotyping of LPIN1 gene SNPs
The LPIN1 exon 3 ϩ17CϾT SNP was genotyped by amplifying genomic DNA using the primers in Table 1 , and the preceding amplification program. This was followed by digestion of the 350-bp product with endonuclease NlaIII. The ϩ17C allele yielded two fragments with sizes 341 and 9-bp after NlaIII digestion. In contrast, the ϩ17T allele yielded three fragments with sizes 207, 134, and 9 bp after NlaIII digestion. The polymorphic fragments were resolved on 2% agarose gels.
The LPIN1 exon 5 935CϾT SNP was genotyped by amplifying genomic DNA using the primers in Table 1 , and the preceding amplification program. This was followed by digestion of the 462-bp product with endonuclease TaqI. The 935C allele yielded three fragments with sizes 211, 135, and 116 bp after TaqI digestion. In contrast, the 935T allele yielded two fragments with sizes 346 and 116 bp after TaqI digestion. The polymorphic fragments were resolved on 2% agarose gels. LPIN1 exon 6 SNPs were genotyped by amplification with the primers in Table 1 , using the preceding program, followed by direct sequencing of genomic DNA using these primers. LPIN1 exon 15 SNP was genotyped by amplifying genomic DNA with the primers in Table 1 , using the preceding program, followed by direct sequencing of genomic DNA using these primers.
Statistical analysis SAS version 6.12 (SAS Institute, Cary, NC, USA) was used for statistical analyses. Allele frequencies were determined from electropheretogram tracings of genomic DNA sequence, except for two SNPs assayed using restriction digestion. Chi-square analysis tested the deviation of genotype frequencies from Hardy-Weinberg predictions, with the nominal P Ͻ 0.05.
Results
Identification of SNPs
Genomic DNA sequencing experiments in 11 FPLD subjects with normal LMNA, 4 BSCL subjects with normal BSCL2 and 10 normal controls uncovered five SNPs. These were a silent SNP ϩ17CϾT in exon 3, a silent SNP 935CϾT in exon 5, silent SNPs 1040GϾA and 1079GϾC in exon 6, and a nonsynonymous SNP 2211CϾT (P616S at the amino acid level) in exon 15. These SNPs are shown in Table 2 . All SNPs were seen in both affected subjects and normal controls. There were no other DNA variants detected in the samples taken from the diseased subjects.
SNP frequencies in normal samples
The observed genotype frequencies of all SNPs did not deviate from the predictions of the Hardy-Weinberg equation. The allele frequency in 100 Caucasians for each SNP is shown in Table 2 .
Discussion
We report (1) primer sets to amplify coding sequences of the LPIN1 gene and (2) use of these primers to sequence genomic DNA. This has resulted in (1) identification of five SNPs in LPIN1 and (2) demonstration that there are no additional coding sequence variants in LPIN1 in lipodystrophic subjects. In the present report, we did not examine the LPIN1 promoter region; therefore, we cannot absolutely rule out the possibility of such SNPs and/or mutations in the affected subjects. However, more than two dozen mutations causing FPLD and BSCL alter the coding sequence and none has been found in promoter or intron sequences (Hegele 2001; Magre et al. 2001) , possibly implying that promoter or intron sequence variants are uncommon in lipodystrophy. Genomic DNA from these subjects will continue to be sequenced as new candidate genes are identified and prioritized for possible involvement in this phenotype. Thus, LPIN1 mutations do not appear to be a common cause of lipodystrophy, although we cannot rule this possibility out because of the limited number of subjects studied herein. It is possible that others might find LPIN1 mutations in lipodystrophic subjects. Despite the absence of disease association in our sample, the reagents described in this report could be helpful to screen the LPIN1 gene for other studies.
